RE: 30 pounds10 Feb 2022 19:44
Docdaneeka,
I'm not convinced that Synairgen needs big pharma as much as big pharma needs Synairgen. Not at all.
Licencing has been Synairgen's preference and as RM pointed out, we will be using the same expertise and service companies as the biggest players in the market- the likes of Catalent, Ashfield, ThermoFisher, etc. So, we are not at such a disadvantage after all. The company now describes itself as 'Agile', and rightly so, agility is something the bigger pharmas will struggle with. There are some benefits to being small :-). Debt finance is also an option for those whose first thought is placing and inevitable SP dilution. Funding will not be an issue IMO. I think the possibilities here are greater than you think.